85 results
8-K
EX-99.1
ZOM
Zomedica Corp
4 Apr 24
Results of Operations and Financial Condition
12:10pm
approximately 23%, which was lower than our top line growth of 33%.
Research and development expense for the year ended December 31, 2023, was $5.7 … million, compared to $2.6 million for the year ended December 31, 2022, an increase of $3.1 million or 123%. The increase in research and development
DEFA14A
ZOM
Zomedica Corp
24 Jan 24
Additional proxy soliciting materials
1:38pm
continuing investments in research and development to fuel new product development and further scaling and improving production to maintain high margins
8-K
EX-99.1
ZOM
Zomedica Corp
13 Nov 23
Results of Operations and Financial Condition
4:16pm
of $0.2 million or 2%, as we start to see leverage on our pathway to profitability.
Research and development expense was $0.9 million, compared to $1.2 …
Expenses
General and administrative
Research and development
Selling and marketing
Loss from operations
Interest income
Interest expense
Gain (loss
8-K
EX-10.1
ylzqu5u
10 Oct 23
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
qlqcetx l5s9v
10 Aug 23
Results of Operations and Financial Condition
4:22pm
8-K
EX-99.1
blqina3z45h5tqgk cr
11 May 23
Results of Operations and Financial Condition
4:27pm
8-K
EX-99.1
qc2ji8yux6g7q25qwq
14 Nov 22
Results of Operations and Financial Condition
4:24pm
8-K
EX-99.1
hbdbdjhs 00tvll
15 Aug 22
Zomedica Announces Second Quarter 2022 Financial Results of $4.2 Million
6:12pm
8-K
EX-99.1
rreql
10 May 22
Results of Operations and Financial Condition
4:28pm
8-K
EX-99.1
pharti
1 Mar 22
Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results
4:52pm
8-K/A
EX-99.2
4tug4x
10 Dec 21
Financial Statements and Exhibits
4:02pm
8-K
EX-99.1
qnaw21b nurqnf
12 Nov 21
Zomedica Announces Third Quarter 2021 Financial Results
4:15pm